Juan Carlos Restrepo
Overview
Explore the profile of Juan Carlos Restrepo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
246
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Codes L, Zapata R, Mendizabal M, Junior A, Restrepo J, Schiavon L, et al.
Ann Hepatol
. 2025 Mar;
:101899.
PMID: 40057036
Liver transplantation (LT) is a well-established therapy for patients with decompensated cirrhosis and early-stage hepatocellular carcinoma. Liver transplantation activity varies sharply across Latin American (LATAM) countries due to differences in...
2.
Lopera V, Restrepo J, Amariles P
Explor Res Clin Soc Pharm
. 2024 Nov;
16:100524.
PMID: 39498228
Background: There is a need to explore pharmacological options for syndrome (FMS), such as medical cannabis. The aim of this systematic review was to synthesize and analyze the available information...
3.
Bustamante C, Pinilla Bonilla L, Restrepo J
Front Integr Neurosci
. 2024 Jul;
18:1417856.
PMID: 39070159
No abstract available.
4.
Restrepo J, Martinez Guevara D, Pareja Lopez A, Montenegro Palacios J, Liscano Y
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001401
Non-small-cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer cases, often diagnosed at advanced stages, which diminishes the effective treatment options and survival rates. This systematic review assesses...
5.
Diaz L, Fuentes-Lopez E, Ayares G, Idalsoaga F, Arnold J, Ayala Valverde M, et al.
JHEP Rep
. 2023 Jul;
5(8):100727.
PMID: 37456675
Background & Aims: Model for End-Stage Liver Disease (MELD) score better predicts mortality in alcohol-associated hepatitis (AH) but could underestimate severity in women and malnourished patients. Using a global cohort,...
6.
Restrepo J, Duenas D, Corredor Z, Liscano Y
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444584
Non-small cell lung cancer (NSCLC) is a significant public health concern with high mortality rates. Recent advancements in genomic data, bioinformatics tools, and the utilization of biomarkers have improved the...
7.
Lopez-Osorio M, Usme-Ciro J, Martinez J, Pelaez-Carvajal D, Hernandez J, Hoyos S, et al.
Virus Res
. 2022 Jun;
318:198847.
PMID: 35697300
Hepatitis C virus (HCV) infection is one of the leading risk factors for end-stage liver disease development worldwide. This RNA virus displays high genetic diversity with 8 genotypes and 96...
8.
Diaz L, Fuentes-Lopez E, Ayares G, Idalsoaga F, Arnold J, Marquez-Lomas A, et al.
Lancet Gastroenterol Hepatol
. 2022 Apr;
7(6):552-559.
PMID: 35430032
Non-alcoholic fatty liver disease (NAFLD) affects 20-25% of the general population and is associated with morbidity, increased mortality, and elevated health-care costs. Most NAFLD risk factors are modifiable and, therefore,...
9.
Arab J, Diaz L, Baeza N, Idalsoaga F, Fuentes-Lopez E, Arnold J, et al.
J Hepatol
. 2021 Jun;
75(5):1026-1033.
PMID: 34166722
Background & Aims: Corticosteroids are the only effective therapy for severe alcohol-associated hepatitis (AH), defined by a model for end-stage liver disease (MELD) score >20. However, there are patients who...
10.
Arab J, Dirchwolf M, Alvares-da-Silva M, Barrera F, Benitez C, Castellanos-Fernandez M, et al.
Ann Hepatol
. 2020 Oct;
19(6):674-690.
PMID: 33031970
Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20-30% of the general population. Furthermore, its prevalence is predicted...